These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34135266)

  • 21. Translating golden retriever muscular dystrophy microarray findings to novel biomarkers for cardiac/skeletal muscle function in Duchenne muscular dystrophy.
    Galindo CL; Soslow JH; Brinkmeyer-Langford CL; Gupte M; Smith HM; Sengsayadeth S; Sawyer DB; Benson DW; Kornegay JN; Markham LW
    Pediatr Res; 2016 Apr; 79(4):629-36. PubMed ID: 26672735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological Assessment of Muscle, Heart, and Whole Body Function in the Canine Model of Duchenne Muscular Dystrophy.
    Hakim CH; Teixeira J; Leach SB; Duan D
    Methods Mol Biol; 2023; 2587():67-103. PubMed ID: 36401025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.
    Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Li J; Nghiem P; Detwiler DA; Larsen CA; Grange RW; Bhavaraju-Sanka RK; Tou S; Keene BP; Howard JF; Wang J; Fan Z; Schatzberg SJ; Styner MA; Flanigan KM; Xiao X; Hoffman EP
    Mamm Genome; 2012 Feb; 23(1-2):85-108. PubMed ID: 22218699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.
    Kornegay JN; Spurney CF; Nghiem PP; Brinkmeyer-Langford CL; Hoffman EP; Nagaraju K
    ILAR J; 2014; 55(1):119-49. PubMed ID: 24936034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-invasive evaluation of muscle disease in the canine model of Duchenne muscular dystrophy by electrical impedance myography.
    Hakim CH; Mijailovic A; Lessa TB; Coates JR; Shin C; Rutkove SB; Duan D
    PLoS One; 2017; 12(3):e0173557. PubMed ID: 28339469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical exertion exacerbates decline in the musculature of an animal model of Duchenne muscular dystrophy.
    Hughes KJ; Rodriguez A; Flatt KM; Ray S; Schuler A; Rodemoyer B; Veerappan V; Cuciarone K; Kullman A; Lim C; Gutta N; Vemuri S; Andriulis V; Niswonger D; Barickman L; Stein W; Singhvi A; Schroeder NE; Vidal-Gadea AG
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3508-3517. PubMed ID: 30755520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy.
    Nitahara-Kasahara Y; Kuraoka M; Guillermo PH; Hayashita-Kinoh H; Maruoka Y; Nakamura-Takahasi A; Kimura K; Takeda S; Okada T
    Stem Cell Res Ther; 2021 Jan; 12(1):78. PubMed ID: 33494794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nitric oxide-dependent attenuation of noradrenaline-induced vasoconstriction is impaired in the canine model of Duchenne muscular dystrophy.
    Kodippili K; Hakim CH; Yang HT; Pan X; Yang NN; Laughlin MH; Terjung RL; Duan D
    J Physiol; 2018 Nov; 596(21):5199-5216. PubMed ID: 30152022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients.
    Etienne J; Joanne P; Catelain C; Riveron S; Bayer AC; Lafable J; Punzon I; Blot S; Agbulut O; Vilquin JT
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1047-1069. PubMed ID: 32157826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Muscular dystrophy in a family of Labrador Retrievers with no muscle dystrophin and a mild phenotype.
    Vieira NM; Guo LT; Estrela E; Kunkel LM; Zatz M; Shelton GD
    Neuromuscul Disord; 2015 May; 25(5):363-70. PubMed ID: 25813339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
    Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
    Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-1beta (IL-1β)-induced Notch ligand Jagged1 suppresses mitogenic action of IL-1β on human dystrophic myogenic cells.
    Nagata Y; Kiyono T; Okamura K; Goto YI; Matsuo M; Ikemoto-Uezumi M; Hashimoto N
    PLoS One; 2017; 12(12):e0188821. PubMed ID: 29194448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative jerk as an outcome measure in nonambulatory Duchenne muscular dystrophy.
    Fujii T; Takeshita E; Iwata Y; Yajima H; Nozaki F; Mori M; Kumada T
    Brain Dev; 2019 Oct; 41(9):796-802. PubMed ID: 31213334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia.
    White Z; Hakim CH; Theret M; Yang NN; Rossi F; Cox D; Francis GA; Straub V; Selby K; Panagiotopoulos C; Duan D; Bernatchez P
    J Clin Lipidol; 2020; 14(4):459-469.e0. PubMed ID: 32593511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
    Maruyama R; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of muscular co-activation and gait variability in children with Duchenne muscular dystrophy: A 2-year follow-up study.
    Rinaldi M; Petrarca M; Romano A; Vasco G; D'Anna C; Bibbo D; Schmid M; Castelli E; Conforto S
    Clin Biomech (Bristol, Avon); 2020 Aug; 78():105101. PubMed ID: 32652381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy.
    Nitahara-Kasahara Y; Kuraoka M; Oda Y; Hayashita-Kinoh H; Takeda S; Okada T
    Stem Cell Res Ther; 2021 Feb; 12(1):105. PubMed ID: 33541428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy.
    Yokota T; Hoffman E; Takeda S
    Methods Mol Biol; 2011; 709():299-312. PubMed ID: 21194037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.